FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1547-1548 November 18, 1993 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The deoxyadenosine analogue 2-chlorodeoxyadenosine is an effective and relatively nontoxic treatment for hairy-cell leukemia¹ and other B-cell neoplasms, including chronic lymphocytic leukemia (CLL)^2,3. In a recent study of 90 patients with CLL, including 62 with advanced disease, the overall rate of response was 44 percent, the most severe toxic effect being myelosuppression⁴. Excellent responses were recently reported in four patients who did not respond to fludarabine therapy, with myelosuppression as the only untoward side effect⁵. We report the occurrence of tumor lysis syndrome after the infusion of 2-chlorodeoxyadenosine in a patient with CLL and bulky lymphadenopathy.

Case Report

A . . . [Full Text of this Article]

Discussion

Source Information

From the Departments of Hematology (E.J.D., S.G., A.P., D.R., E.A.R.) and Pathology (E.O.), Hadassah University Hospital, Ein Kerem, Jerusalem, Israel.

Address reprint requests to Dr. Dann at Hadassah University Hospital, Kiryat Hadassah, P.O. Box 12000, il-91 120 Jerusalem, Israel.

References

Related Letters:

Tumor Lysis Syndrome after Treatment of Chronic Lymphocytic Leukemia with Cladribine
Trendle M. C., Tefferi A., Dann E. J., Rachmilewitz E. A., Rund D.
Extract | Full Text  
N Engl J Med 1994; 330:1090, Apr 14, 1994. Correspondence

This article has been cited by other articles:

• Krishna, V. M., Carey, R. W., Bloch, K. J. (2003). Marked Increase in Serum IgM during Treatment of Waldenstrom's Macroglobulinemia with Cladribine. NEJM 348: 2045-2046 [Full Text]  
• Sewani, H. H., Rabatin, J. T. (2002). Acute Tumor Lysis Syndrome in a Patient With Mixed Small Cell and Non-Small Cell Tumor. Mayo Clin Proc. 77: 722-728 [Abstract]  
• Morris, A. K, Kolesar, J. M, Kuhn, J. G (1997). Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine. J Oncol Pharm Pract 3: 94-109  
• Fidias, P., Chabner, B. A., Grossbard, M. L. (1996). Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders. The Oncologist 1: 125-139 [Abstract] [Full Text]  
• Trendle, M. C., Tefferi, A., Dann, E. J., Rachmilewitz, E. A., Rund, D. (1994). Tumor Lysis Syndrome after Treatment of Chronic Lymphocytic Leukemia with Cladribine. NEJM 330: 1090-1090 [Full Text]